about
Intestinal permeability--a new target for disease prevention and therapyResveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic controlMetagenome and metabolism: the tissue microbiota hypothesis.[Intestinal microbiota and novel therapeutic perspectives for the treatment of metabolic diseases].Periodontal dysbiosis linked to periodontitis is associated with cardiometabolic adaptation to high-fat diet in mice.Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice.[Metabolic therapy at the edge between human hosts and gut microbes].Lipid-induced peroxidation in the intestine is involved in glucose homeostasis imbalance in miceCirculating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance.The gut microbiota profile is associated with insulin action in humans.Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences.High-fat diet induces periodontitis in mice through lipopolysaccharides (LPS) receptor signaling: protective action of estrogensCD14 modulates inflammation-driven insulin resistance.Defective NOD2 peptidoglycan sensing promotes diet-induced inflammation, dysbiosis, and insulin resistance.Gut microbiota and diabetes: from pathogenesis to therapeutic perspective.The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORγt and Controls Metabolic Disease.Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota.Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanismIntestinal microflora and metabolic diseases.The gut microbiota ecology: a new opportunity for the treatment of metabolic diseases?A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism.Transfer of dysbiotic gut microbiota has beneficial effects on host liver metabolism.Intestinal MicrobiOMICS to define health and disease in human and mice.Managing the manager: gut microbes, stem cells and metabolism.Young microbes for adult obesity.Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis.Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response.Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept.A role for adipocyte-derived lipopolysaccharide-binding protein in inflammation- and obesity-associated adipose tissue dysfunction.Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver.Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.Gestational diabetes is associated with changes in placental microbiota and microbiome.Adiponectin isoforms are not associated with the severity of coronary atherosclerosis but with undiagnosed diabetes in patients affected by stable CAD.Gut Microbiota Interacts With Brain Microstructure and Function.Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms.Molecular Paths linking Metabolic Diseases, Gut Microbiota Dysbiosis and Enterobacteria Infections.Gut Microbiota Interacts with Markers of Adipose Tissue Browning, Insulin Action and Plasma Acetate in Morbid Obesity.Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes.Oral health and microbiota status in professional rugby players: A case-control studyPublisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
P50
Q27015884-0EC2B91D-55FF-47E6-82D6-61DD866EC4D4Q28743932-E107E8CF-F0F2-43AA-B651-8A0097AC63DBQ30353335-B6FC4369-2899-46A2-A0DF-2215407B706CQ30353345-2D924923-E2A3-4EF8-A835-39717141C7E1Q30386301-F5BC91D8-39B1-4A78-A056-9B15CA6F496DQ30397725-09700D51-8ADC-4F89-9FD4-26D9FF795584Q33355158-90A2A198-0451-4578-B28E-B3317E9C87E1Q33940826-FDF68FDC-17FF-4F3E-AF2E-8BE9F877FDB0Q34241743-DD961CC1-2517-4031-8CEA-306F49B731D7Q34308355-C9BA547B-C923-4AFE-827B-5C0239377150Q34324267-D16179D7-FDEE-4D32-B001-978CCD7C1B45Q34469634-C61B65F1-914B-4705-B4B1-0D4056BAF213Q35123567-DA0723E7-6A5B-4538-AFBE-30FDAA2E2BCEQ35192440-3368C316-F716-4F4C-9891-826F2D260017Q35573510-2EDD9E80-1790-4952-BA31-A50C85A4FF60Q35685817-457023E0-5401-4A29-8C06-576B5A601E19Q35799019-51EA2125-9ED8-430F-908C-AF865C3CF0A5Q37173378-B10D3F3E-940F-45AC-879A-E1545C1ACF47Q37472427-ACDB994C-FCB0-49AA-A1DD-835D67AB8144Q37501808-786ABBD4-F37A-490B-B345-BE82B66C6DCDQ37607539-51F1A5D8-998D-4773-B3F4-A4640F94EC48Q37727703-7AEE97C2-2A7D-43D8-84F2-9EE54BBF41A2Q37961943-B6723267-D95C-4C85-A8E5-8159D32B94AFQ38181745-29016F99-3191-43A8-B46C-FB4140802208Q38822984-5DEEF9CC-6BE1-46DE-810D-03C297E12ACCQ39379029-B7B7B1F1-1942-4C23-9350-096E7B1974E6Q40807681-8ABF1560-CDC8-4C84-B129-24F2CD60DD2BQ42619039-C6885348-FEF0-4740-B37D-870B8104EE64Q42814704-D28BBB4A-768A-4826-9BE3-B8BB89A0B60AQ45052723-E41D032F-A54E-49B7-B126-13E79C101906Q46362610-9D1B409F-9C85-4385-9668-76B27A141A8FQ46506319-C15768B4-35E0-4479-8FCB-344A8AB72AB4Q46601041-6A90556D-9F60-4FE1-B626-D1187588B72CQ46658369-44F4D2A5-EECB-40EA-AB8B-ED1B606C20A5Q48024001-7B0D684D-6E68-417E-B4A3-37767B62140EQ49644754-914690E6-610F-4C23-8970-EC22F83D8B4CQ50144818-DEA21A4D-D9A5-4096-9301-E506CB25C923Q53538930-7115146E-84C9-445B-9C6A-A28ABD662D5DQ57187030-F770A5EB-4BFB-4A78-8E87-90A03BC35F4BQ57518107-3AFB5233-FC36-4AFF-B48D-BB5235BCC487
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
M Serino
@ast
M Serino
@en
M Serino
@es
M Serino
@nl
type
label
M Serino
@ast
M Serino
@en
M Serino
@es
M Serino
@nl
prefLabel
M Serino
@ast
M Serino
@en
M Serino
@es
M Serino
@nl
P106
P31
P496
0000-0003-4644-8532